Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:GNVC's Cash to Debt is ranked higher than
99% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:GNVC: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:GNVC' s Cash to Debt Range Over the Past 10 Years
Min: 0.83  Med: 24.15 Max: No Debt
Current: No Debt
Equity to Asset 0.65
NAS:GNVC's Equity to Asset is ranked lower than
53% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:GNVC: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
NAS:GNVC' s Equity to Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.74 Max: 0.89
Current: 0.65
0.35
0.89
F-Score: 1
Z-Score: -43.25
M-Score: -1.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1039.75
NAS:GNVC's Operating margin (%) is ranked lower than
77% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:GNVC: -1039.75 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:GNVC' s Operating margin (%) Range Over the Past 10 Years
Min: -1039.75  Med: -140.33 Max: -42
Current: -1039.75
-1039.75
-42
Net-margin (%) -909.71
NAS:GNVC's Net-margin (%) is ranked lower than
77% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:GNVC: -909.71 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:GNVC' s Net-margin (%) Range Over the Past 10 Years
Min: -909.71  Med: -132.85 Max: -41.63
Current: -909.71
-909.71
-41.63
ROE (%) -82.21
NAS:GNVC's ROE (%) is ranked lower than
75% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:GNVC: -82.21 )
Ranked among companies with meaningful ROE (%) only.
NAS:GNVC' s ROE (%) Range Over the Past 10 Years
Min: -177.18  Med: -66.09 Max: -25.24
Current: -82.21
-177.18
-25.24
ROA (%) -61.81
NAS:GNVC's ROA (%) is ranked lower than
74% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:GNVC: -61.81 )
Ranked among companies with meaningful ROA (%) only.
NAS:GNVC' s ROA (%) Range Over the Past 10 Years
Min: -101.98  Med: -53.41 Max: -21.39
Current: -61.81
-101.98
-21.39
ROC (Joel Greenblatt) (%) -2286.46
NAS:GNVC's ROC (Joel Greenblatt) (%) is ranked lower than
71% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:GNVC: -2286.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:GNVC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2366.49  Med: -1523.24 Max: -573.01
Current: -2286.46
-2366.49
-573.01
Revenue Growth (3Y)(%) -58.20
NAS:GNVC's Revenue Growth (3Y)(%) is ranked lower than
87% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:GNVC: -58.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:GNVC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.8  Med: -20.95 Max: 6
Current: -58.2
-66.8
6
EBITDA Growth (3Y)(%) -28.90
NAS:GNVC's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:GNVC: -28.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:GNVC' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -43.5  Med: -24.3 Max: 12.1
Current: -28.9
-43.5
12.1
EPS Growth (3Y)(%) -29.00
NAS:GNVC's EPS Growth (3Y)(%) is ranked lower than
79% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NAS:GNVC: -29.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:GNVC' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.8  Med: -24.8 Max: 8.6
Current: -29
-42.8
8.6
» NAS:GNVC's 10-Y Financials

Financials (Next Earnings Date: 2017-03-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

GNVC Guru Trades in Q4 2015

Jim Simons 65,700 sh (+15.47%)
» More
Q1 2016

GNVC Guru Trades in Q1 2016

Jim Simons 120,900 sh (+84.02%)
» More
Q2 2016

GNVC Guru Trades in Q2 2016

Jim Simons 156,500 sh (+29.45%)
» More
Q3 2016

GNVC Guru Trades in Q3 2016

Jim Simons 184,500 sh (+17.89%)
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:SGBI, OTCPK:PVOTF, NAS:BLPH, NAS:OPXA, OTCPK:PPCH, OTCPK:FPMI, AMEX:BPMX, OTCPK:ENUM, OTCPK:HDVY, OTCPK:NMUS, OTCPK:CDXI, AMEX:APHB, OTCPK:ENDV, OTCPK:VRTHF, NAS:JAGX, OTCPK:BPSR, NAS:LPTN, OTCPK:BLVKF, NAS:CBIO, OTCPK:BTHE » details
Traded in other countries:GVC2.Germany,
Genvec Inc is a biopharmaceutical company. The Company is engaged in leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines.

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.

Ratios

vs
industry
vs
history
P/B 1.17
GNVC's P/B is ranked lower than
87% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. GNVC: 1.17 )
Ranked among companies with meaningful P/B only.
GNVC' s P/B Range Over the Past 10 Years
Min: 0.42  Med: 3.27 Max: 41.5
Current: 1.17
0.42
41.5
P/S 8.93
GNVC's P/S is ranked higher than
56% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. GNVC: 8.93 )
Ranked among companies with meaningful P/S only.
GNVC' s P/S Range Over the Past 10 Years
Min: 0.62  Med: 5.08 Max: 42.97
Current: 8.93
0.62
42.97
EV-to-EBIT 0.22
GNVC's EV-to-EBIT is ranked higher than
93% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. GNVC: 0.22 )
Ranked among companies with meaningful EV-to-EBIT only.
GNVC' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.2  Med: -2.7 Max: 0.5
Current: 0.22
-24.2
0.5
EV-to-EBITDA 0.22
GNVC's EV-to-EBITDA is ranked higher than
93% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. GNVC: 0.22 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNVC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.7  Med: -2.8 Max: 0.5
Current: 0.22
-25.7
0.5
Current Ratio 6.00
GNVC's Current Ratio is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. GNVC: 6.00 )
Ranked among companies with meaningful Current Ratio only.
GNVC' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.4 Max: 8.55
Current: 6
1.46
8.55
Quick Ratio 6.00
GNVC's Quick Ratio is ranked higher than
62% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. GNVC: 6.00 )
Ranked among companies with meaningful Quick Ratio only.
GNVC' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 4.4 Max: 8.55
Current: 6
1.46
8.55
Days Sales Outstanding 98.98
GNVC's Days Sales Outstanding is ranked lower than
72% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. GNVC: 98.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
GNVC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.64  Med: 41.81 Max: 98.98
Current: 98.98
19.64
98.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.30
GNVC's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. GNVC: -10.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNVC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -139.6  Med: -12.95 Max: -2
Current: -10.3
-139.6
-2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.38
GNVC's Price/Net Cash is ranked lower than
71% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. GNVC: 1.38 )
Ranked among companies with meaningful Price/Net Cash only.
GNVC' s Price/Net Cash Range Over the Past 10 Years
Min: 0.89  Med: 6.05 Max: 35.2
Current: 1.38
0.89
35.2
Price/Net Current Asset Value 1.25
GNVC's Price/Net Current Asset Value is ranked lower than
75% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. GNVC: 1.25 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GNVC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.67  Med: 4.84 Max: 18.38
Current: 1.25
0.67
18.38
Price/Tangible Book 1.18
GNVC's Price/Tangible Book is ranked lower than
82% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. GNVC: 1.18 )
Ranked among companies with meaningful Price/Tangible Book only.
GNVC' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.58  Med: 3.4 Max: 16.66
Current: 1.18
0.58
16.66
Price/Median PS Value 1.75
GNVC's Price/Median PS Value is ranked lower than
81% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. GNVC: 1.75 )
Ranked among companies with meaningful Price/Median PS Value only.
GNVC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.17  Med: 1.2 Max: 6.81
Current: 1.75
0.17
6.81
Earnings Yield (Greenblatt) (%) 445.73
GNVC's Earnings Yield (Greenblatt) (%) is ranked higher than
98% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. GNVC: 445.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GNVC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 217.6  Med: 383.75 Max: 17011.4
Current: 445.73
217.6
17011.4

More Statistics

Revenue (TTM) (Mil) $0.65
EPS (TTM) $ -3.10
Beta1.29
Short Percentage of Float1.08%
52-Week Range $2.70 - 20.80
Shares Outstanding (Mil)2.27

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1 1 1 2
EPS ($) -1.73 -2.81 -2.70 -3.00
EPS w/o NRI ($) -1.73 -2.81 -2.70 -3.00
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
GENVEC INC Financials Dec 06 2016
GenVec Effects 1-for-10 Reverse Stock Split Dec 01 2016
GENVEC INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Dec 01 2016
GenVec Effects 1-for-10 Reverse Stock Split Dec 01 2016
GENVEC INC Files SEC form 8-K, Other Events Nov 16 2016
GenVec, Inc. :GNVC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 04 2016
GenVec Reports Third Quarter 2016 Financial Results Nov 04 2016
GenVec Reports Third Quarter 2016 Financial Results Nov 04 2016
GENVEC INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD... Oct 24 2016
GenVec To Present At 2016 Cell & Gene Meeting On The Mesa Sep 28 2016
GENVEC INC Files SEC form 8-K, Regulation FD Disclosure Sep 01 2016
GENVEC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or... Aug 24 2016
GenVec, Inc. :GNVC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 05 2016
GenVec Reports Second Quarter 2016 Financial Results Aug 05 2016
GenVec Reports Second Quarter 2016 Financial Results Aug 05 2016
GENVEC INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 27 2016
FDA Lifts Clinical Hold On CGF166 Jul 25 2016
FDA Lifts Clinical Hold On CGF166 Jul 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)